Annual Drug Repositioning Conference 2012

Join us in San Francisco for the 2nd Annual Drug Repositioning Conference, where presenters and panelists will share with the audience best practices, new technologies, case studies, and regulatory developments in drug repositioning and indications discovery.

Drug repositioning lowers the cost of drug discovery, as preclinical and early stage clinical trials have already been completed. This leads to a larger return on investment for new drugs. Not only have companies been able to use drugs that have not made it through clinical trials; they are also finding new ways to use drugs that already on the market. Companies have found new indications for currently marketed drugs and use in combination therapy as well. Life cycle management is also becoming more important to combat generic copies and increase ROI.

Why Attend

• Learn the opportunities and challenges of drug rediscovery

• Hear successful drug repositioning case studies

• Determine how to find drug repositioning opportunities

• Learn about product life cycle management through new indications and combination therapy

Who Should Attend

• Pharmaceutical Companies

• Specialist Repositioning Companies

• Contract Research Organizations

• Mid Cap/SME Biotechs

• Government/Regulatory Bodies

• Venture Capital/Investors

• Academic/Research Institutes

• NGOs/Public Health

• Bioinformatics Companies

• Law Firms

• Consultants